Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Statement of Chairwoman Ramirez, Commissioner Brill, and Commissioner McSweeny - In the Matter of True Ultimate Standards Everywhere, Inc. (TRUSTe)
Partial Dissent of Commissioner Maureen K. Ohlhausen - In the Matter of True Ultimate Standards Everywhere, Inc. (“TRUSTe”)
Dissenting Statement of Commissioner Maureen K. Ohlhausen - In the Matter of AmeriGas and Blue Rhino
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill Federal Trade Commission - In the Matter of Ferrellgas Partners, L.P., et al.
Concurring Statement of Commissioner Joshua D. Wright - In the Matter of Ferrellgas Partners, L.P.
Shire Viropharma, Inc
Comment Filed by Jessica Rich, Discussing Voluntary Code of Conduct for Utilities and Third Parties Providing Consumer Energy Use Services
Paglia, Ralph
HealthyLife Sciences, LLC, In the Matter of
John Matthew Dwyer III, In the Matter of
Acquinity Interactive, LLC, et al.
Zaken Group, The, also d/b/a The Zaken Corporation, QuickSell, and QuikSell and Tiran Zaken
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.